AUROBINDO PHARMA
This has reference to your aforesaid E-mail dated October 7, 2019, seeking clarification on news item appearing in www.thehindubusinessline.com.
In this regard, we provide the following clarification: Pursuant to Regulation 30 of the SESI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration (USFDA) conducted a cGMP inspection at our Unit 7 manufacturing facility from September 19-27, 2019.
The inspection ended with 7 observations. We believe none of the observations are related to data integrity. The Company is confident of addressing these issues within the stipulated timeline.
Source : Bse